Characterization of renal tubular apical efflux of zonampanel, an α-amino-3-hydroxy-5- methylisoxazole-4-propionate receptor antagonist, in humans

References

• Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Molecular Pharmacology 2007; 71(6)1591–1597
   PubMedGoogle Scholar
• Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. Journal of Pharmacological Sciences 2004; 94(3)297–304
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. Journal of the American Society of Nephrology 2007; 18(1)37–45
   PubMedGoogle Scholar
• Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metabolism and Disposition 2004; 32(10)1096–1102
   PubMedGoogle Scholar
• Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition 2007; 35(8)1333–1340
   PubMed Web of Science ®Google Scholar
• Huls M, Brown CD, Windass AS, Sayer R, Van den Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney International 2008; 73(2)220–225
   PubMed Web of Science ®Google Scholar
• Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Molecular Pharmacology 2007; 71(2)619–627
   PubMed Web of Science ®Google Scholar
• Kawasaki-Yatsugi S, Yatsugi S, Takahashi M, Toya T, Ichiki C, Shimizu-Sasamata M, Yamaguchi T, Minematsu K. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Research 1998; 793(1–2)39–46
   PubMedGoogle Scholar
• Minematsu T, Sohda KY, Hashimoto T, Imai H, Usui T, Kamimura H. Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers. Xenobiotica 2005; 35(4)359–371
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita K, et al. Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. Journal of the American Society of Nephrology 2005; 16(12)3498–3506
   PubMedGoogle Scholar
• Mizuno N, Takahashi T, Kusuhara H, Schuetz JD, Niwa T, Sugiyama Y. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one). Drug Metabolism and Disposition 2007; 35(11)2045–2052
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, Sugiyama Y. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. Journal of Pharmacology and Experimental Therapeutics 2007; 322(3)1162–1170
   PubMed Web of Science ®Google Scholar
• Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR. Mechanism of active renal tubular efflux of tenofovir. Antimicrobial Agents and Chemotherapy 2006; 50(10)3297–3304
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sato H, Sugiyama Y. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 2005; 45: 689–723
   PubMed Web of Science ®Google Scholar
• Smeets PH, Van Aubel RA, Wouterse AC, Van den Heuvel JJ, Russel FG. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. Journal of the American Society of Nephrology 2004; 15(11)2828–2835
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ni JW, Kawasaki-Yatsugi S, Toya T, Yatsugi SI, Shimizu-Sasamata M, Koshiya K, Shishikura JI, Sakamoto S, Yamaguchi T. YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats. Journal of Pharmacology and Experimental Therapeutics 1998; 284(2)467–473
   PubMed Web of Science ®Google Scholar
• Takeda M, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. European Journal of Pharmacology 2002; 438(3)137–142
   PubMed Web of Science ®Google Scholar
• Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: Putative efflux pump for urinary cAMP and cGMP. Journal of the American Society of Nephrology 2002; 13(3)595–603
   PubMed Web of Science ®Google Scholar
• Van Crugten J, Bochner F, Keal J, Somogyi A. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. Journal of Pharmacology and Experimental Therapeutics 1986; 236(2)481–487
   PubMedGoogle Scholar
• Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, Schuetz JD, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metabolism and Disposition 2007; 35(12)2166–2176
   PubMed Web of Science ®Google Scholar